| abstract |
The invention relates in general to methods for predicting the safety of a pharmacological treatment using a nicotinic cholinergic receptor agonist drug, such as varenicline, said methods being based on determining at least one allele of one or more of single-nucleotide polymorphisms (SNP) rs9479757, rs7930792, rs12423809, rs4251417, rs7146, rs477292, rs495491, rs3778151, rs763132, rs4474069 and rs1183035, or of any SNP of the corresponding linkage blocks thereof, in a biological sample from a subject. |